Morgan Dempsey Capital Management LLC raised its position in shares of Mednax Inc. (NYSE:MD) by 147.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,192 shares of the company’s stock after buying an additional 1,307 shares during the period. Morgan Dempsey Capital Management LLC’s holdings in Mednax were worth $159,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. Montag & Caldwell LLC boosted its stake in shares of Mednax by 0.5% in the second quarter. Montag & Caldwell LLC now owns 12,900 shares of the company’s stock worth $934,000 after buying an additional 60 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Mednax by 0.6% in the second quarter. Nisa Investment Advisors LLC now owns 32,420 shares of the company’s stock worth $2,348,000 after buying an additional 200 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in shares of Mednax by 6.9% in the second quarter. State of Alaska Department of Revenue now owns 9,780 shares of the company’s stock worth $708,000 after buying an additional 630 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in shares of Mednax by 3.0% in the second quarter. Rice Hall James & Associates LLC now owns 28,160 shares of the company’s stock worth $2,040,000 after buying an additional 833 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its stake in shares of Mednax by 0.6% in the first quarter. Lazard Asset Management LLC now owns 167,229 shares of the company’s stock worth $10,806,000 after buying an additional 1,000 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.
Shares of Mednax Inc. (NYSE:MD) traded down 1.17% during mid-day trading on Friday, reaching $66.12. The company’s stock had a trading volume of 692,755 shares. The firm has a market capitalization of $6.10 billion, a PE ratio of 18.45 and a beta of 0.54. The firm has a 50-day moving average of $65.52 and a 200-day moving average of $68.29. Mednax Inc. has a 52 week low of $61.40 and a 52 week high of $83.20.
Mednax (NYSE:MD) last issued its earnings results on Thursday, July 28th. The company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.07 by $0.04. The firm earned $772 million during the quarter, compared to analysts’ expectations of $775.68 million. Mednax had a return on equity of 14.88% and a net margin of 11.17%. The company’s quarterly revenue was up 14.1% compared to the same quarter last year. During the same period last year, the business posted $0.90 earnings per share. Equities research analysts forecast that Mednax Inc. will post $4.14 earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research cut Mednax from a “hold” rating to a “sell” rating in a research note on Wednesday, September 28th. Mizuho reissued a “buy” rating and set a $79.00 target price on shares of Mednax in a research note on Tuesday, September 20th. Jefferies Group lowered their target price on Mednax from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Friday, August 26th. Citigroup Inc. lowered their target price on Mednax from $76.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 17th. Finally, JPMorgan Chase & Co. lowered their target price on Mednax from $85.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 29th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $76.11.
In related news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $65.01, for a total value of $97,515.00. Following the transaction, the director now directly owns 12,755 shares of the company’s stock, valued at approximately $829,202.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is owned by corporate insiders.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax Inc. (NYSE:MD).
Receive News & Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.